Jingdong Yang

Dr. Jingdong Yang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
VNVan T. Nguyen
Van T. Nguyen
Biruk Tesfaye BirhanuBiruk Tesfaye Birhanu
Biruk Tesfaye Birhanu
VMVega Miguel-Ruano
Vega Miguel-Ruano
CKChoon Kim
Choon Kim
MBMayte Batuecas
Mayte Batuecas
SMShahriar Mobashery
Shahriar Mobashery

21 September 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YQYuanyuan Qian
Yuanyuan Qian
Biruk Tesfaye BirhanuBiruk Tesfaye Birhanu
Biruk Tesfaye Birhanu
JYJingdong Yang
Jingdong Yang
DDDerong Ding
Derong Ding
JJJeshina Janardhanan
Jeshina Janardhanan
MCMayland Chang
Mayland Chang

14 January 2026 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
YZYujun Zhou
Yujun Zhou
JYJingdong Yang
Jingdong Yang
YHYue Huang
Yue Huang
KGKehan Guo
Kehan Guo
ZEZoe Emory
Zoe Emory
XZXiangliang Zhang
Xiangliang Zhang

30 January 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
Choon KimChoon Kim
Choon Kim
RMRafael Molina Monterrubio
Rafael Molina Monterrubio
MLMijoon Lee
Mijoon Lee
AGAlba Garay-Alvarez
Alba Garay-Alvarez
JYJingdong Yang
Jingdong Yang
SMShahriar Mobashery
Shahriar Mobashery

26 April 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JYJingdong Yang
Jingdong Yang
YQYuanyuan Qian
Yuanyuan Qian
Choon KimChoon Kim
Choon Kim
Biruk Tesfaye BirhanuBiruk Tesfaye Birhanu
Biruk Tesfaye Birhanu
CMCarlos Cal Y Mayor-Luna
Carlos Cal Y Mayor-Luna
MCMayland Chang
Mayland Chang

25 August 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
MSMonica Stefaniak
Monica Stefaniak
VGVijay Singh Gondil
Vijay Singh Gondil
JYJingdong Yang
Jingdong Yang
AOAdil Omar
Adil Omar
AOAllen Oliver
Allen Oliver
CMChristian Corey Melander
Christian Corey Melander
Background/Objectives: The emergence of methicillin-resistant Staphylococcus aureus (MRSA) highlights the need for new antibacterial agents. Here, we report the identification and evaluation of a novel Gram-positive selective antibacterial: NDM-552. Methods: Antibacterial activity was determined by broth microdilution against a panel of Gram-positive and Gram-negative pathogens. Mechanistic studies included BOCILLIN-FL competition assays, microscale thermophoresis (MST), and antibiotic interaction with oxacillin and moenomycin. Additionally, time–kill analyses, frequency-of-resistance measurements, cytotoxicity assays, plasma stability studies, and a murine wound infection model were performed to characterize NDM-552. Results: NDM-552 exhibits activity against Gram-positive pathogens including S. aureus, Enterococcus faecium, and Staphylococcus epidermidis, with minimum inhibitory concentrations (MICs) of 1–2 µg/mL. NDM-552 displays no activity against Gram-negative bacteria. NDM-552 displays bacteriostatic activity against MRSA and additive interactions with oxacillin and moenomycin. The frequency of resistance in MRSA is low (2.39 × 10−9). BOCILLIN-FL competition assays and MST binding analysis identify the essential penicillin-binding protein 2 (PBP2) as the potential target of NDM-552. NDM-552 demonstrates acceptable cytotoxicity, favorable plasma stability, and reduces bacterial burden in a murine wound infection model. Conclusions: NDM-552 is a potent Gram-positive selective antibacterial agent that potentially targets PBP2-associated cell wall biosynthesis and exhibits in vivo efficacy against MRSA. Findings establish NDM-552 as a promising scaffold for the development of new antibacterial agents.